Gemcitabine cytotoxicity of human malignant glioma cells: modulation by antioxidants, BCL-2 and dexamethasone.

No abstract is available for this paper.

• Publication year

  1999

• Venue

  European Journal of Pharmacology

• Publication date

  1999-01-22

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1016/S0014-2999(98)00883-8PMID 9988115
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The Bcl-2 protein family: arbiters of cell survival.

  1998cited by this paper
• Predicting chemoresistance in human malignant glioma cells: The role of molecular genetic analyses

  1998cited by this paper
• Chemosensitivity of human malignant glioma: modulation by p53 gene transfer

  1998cited by this paper
• Predicting response to cancer chemotherapy: the role of p53

  1998cited by this paper
• Dexamethasone-mediated protection from drug cytotoxicity: association with p21WAF1/CIP1 protein accumulation?

  1998cited by this paper
• Cooperative Interception of Neuronal Apoptosis by BCL‐2 and BAG‐1 Expression: Prevention of Caspase Activation and Reduced Production of Reactive Oxygen Species

  1997cited by this paper
• Gemcitabine in Solid Tumors – Present Status and Further Development

  1997cited by this paper
• Gemcitabine. A review of its pharmacology and clinical potential in non-small cell lung cancer and pancreatic cancer.

  1997cited by this paper
• Chemotherapy of human malignant glioma

  1997cited by this paper
• Topoisomerase‐I inhibitors for human malignant glioma: Differential modulation of p53, p21, bax and bcl‐2 expression and of CD95‐mediated apoptosis by camptothecin and β‐lapachone

  1997cited by this paper
• A model for p53-induced apoptosis

  1997cited by this paper
• Inhibitory effects of the nucleoside analogue gemcitabine on prostatic carcinoma cells

  1996cited by this paper
• 2′,2′‐Difluorodeoxycytidine (Gemcitabine) Induces Apoptosis in Myeloma Cell Lines Resistant to Steroids and 2‐Chlorodeoxyadenosine (2‐CdA)

  1996cited by this paper
• Excision of 2',2'-difluorodeoxycytidine (gemcitabine) monophosphate residues from DNA.

  1996cited by this paper
• Clinical, toxicological and pharmacological aspects of gemcitabine.

  1996cited by this paper
• Gemcitabine: metabolism, mechanisms of action, and self-potentiation.

  1995cited by this paper
• Gemcitabine: a modulator of intracellular nucleotide and deoxynucleotide metabolism.

  1995cited by this paper
• Comparison of the induction of apoptosis in human leukemic cell lines by 2',2'-difluorodeoxycytidine (gemcitabine) and cytosine arabinoside.

  1995cited by this paper
• Radiosensitization of human tumor cells by gemcitabine in vitro.

  1995cited by this paper
• Gemcitabine: a modulator of intracellular nucleotide and deoxynucleotide metabolism.

  1995cited by this paper
• Evaluation of the cytotoxic activity of gemcitabine in primary cultures of tumor cells from patients with hematologic or solid tumors.

  1995cited by this paper
• Protooncogene bcl-2 gene transfer abrogates Fas/APO-1 antibody-mediated apoptosis of human malignant glioma cells and confers resistance to chemotherapeutic drugs and therapeutic irradiation.

  1995cited by this paper
• Analysis of the p53 gene and its expression in human glioblastoma cells.

  1994cited by this paper
• Development and molecular characterization of a 2',2'-difluorodeoxycytidine-resistant variant of the human ovarian carcinoma cell line A2780.

  1994cited by this paper
• Disposition of gemcitabine in rat and dog after single and multiple dosings.

  1994cited by this paper
• Metabolism of 2',2'-difluoro-2'-deoxycytidine and radiation sensitization of human colon carcinoma cells.

  1994cited by this paper
• Comparison of antineoplastic activity of 2',2'-difluorodeoxycytidine and cytosine arabinoside against human myeloid and lymphoid leukemic cells

  1991cited by this paper
• Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2',2'-difluorodeoxycytidine.

  1990cited by this paper

• A fluorescent gemcitabine prodrug that follows a nucleoside transporter-independent internalization and bears enhanced therapeutic efficacy with respect to gemcitabine.

  2024cites this paper
• Recent advances on anticancer and antimicrobial activities of directly-fluorinated five-membered heterocycles and their benzo-fused systems

  2024cites this paper
• Repurposing gemcitabine for glioblastoma treatment: the role of drug-conjugates and nanoparticles as drug delivery systems

  2024cites this paper
• Continuous iontronic chemotherapy reduces brain tumor growth in embryonic avian in vivo models.

  2024cites this paper
• Targeted Chemotherapy of Glioblastoma Spheroids with an Iontronic Pump

  2021cites this paper
• The Sledgehammer in Precision Medicine: Dexamethasone and Immunotherapeutic Treatment of Glioma

  2021cites this paper
• A Novel Three-Dimensional Glioma Blood-Brain Barrier Model for High-Throughput Testing of Tumoricidal Capability

  2019cites this paper
• Cyanine-Gemcitabine Conjugates as Targeted Theranostic Agents for Glioblastoma Tumor Cells.

  2019cites this paper
• Role of gemcitabine as a radiosensitizer in Glioblastoma Multiforme treatment

  2018cites this paper
• Injectable nanomedicine hydrogel for local chemotherapy of glioblastoma after surgical resection

  2017cites this paper
• Gemcitabine and glioblastoma: challenges and current perspectives.

  2017cites this paper
• PEGylated squalenoyl-gemcitabine nanoparticles for the treatment of glioblastoma.

  2016cites this paper
• Selective glucocorticoid receptor-activating adjuvant therapy in cancer treatments

  2016cites this paper
• The triterpene echinocystic acid and its 3-O-glucoside derivative are revealed as potent and selective glucocorticoid receptor agonists.

  2016cites this paper
• Lauroyl-gemcitabine-loaded lipid nanocapsule hydrogel for the treatment of glioblastoma.

  2016cites this paper
• Fluorinated isoxazolines and isoxazoles: A synthetic perspective

  2015cites this paper
• Potential interactions of prescription and over‐the‐counter medications having antioxidant capabilities with radiation and chemotherapy

  2015cites this paper
• Sustained delivery of cytarabine-loaded vesicular phospholipid gels for treatment of xenografted glioma.

  2014cites this paper
• Aprepitant Reduces Chemotherapy-Induced Vomiting in Children and Young Adults With Brain Tumors

  2014cites this paper
• The Role of the ATR-CHEK1 Pathway in Therapeutic Resistance Resulting from Distal 11q Loss in Carcinoma Cells

  2013cites this paper
• The C-terminal region of Bfl-1 sensitizes non-small cell lung cancer to gemcitabine-induced apoptosis by suppressing NF-κB activity and down-regulating Bfl-1

  2011cites this paper
• Role of glucocorticoids in breast cancer.

  2010cites this paper
• The role of 5'-nucleotidases and Deoxynucleoside Kinases in Responses to Nucleoside Analogues

  2010cites this paper
• Optimizing Emetic Control in Children Receiving Antineoplastic Therapy

  2010cites this paper
• The Effects of p53 and p53R2 Expression on Gemcitabine-Mediated Cytotoxicity and Radiosensitization.

  2009cites this paper
• Glucocorticoid-mediated apoptosis resistance of solid tumors.

  2009cites this paper
• Dexamethasone inhibits camptothecin-induced apoptosis in C6-glioma via activation of Stat5/Bcl-xL pathway.

  2009cites this paper
• Fixed dose-rate gemcitabine as radiosensitizer for newly diagnosed glioblastoma: a dose-finding study

  2008cites this paper
• The Role of Glucose Metabolism and Glucose-Associated Signalling in Cancer

  2008cites this paper
• Fluorinated Nucleosides: Synthesis and Biological Implication.

  2008cites this paper
• Regulation of differential pro- and anti-apoptotic signaling by glucocorticoids

  2007cites this paper
• Pharmacokinetics of gemcitabine in tumor and non-tumor extracellular fluid of brain: an in vivo assessment in rats employing intracerebral microdialysis

  2007cites this paper
• Drug Targeting of α-Synuclein Oligomerization in Synucleinopathies

  2007cites this paper
• Image-guided convection-enhanced delivery of gemcitabine to the brainstem.

  2007cites this paper
• Cell Cycle Arrest by Glucocorticoids May Protect Normal Tissue and Solid Tumors from Cancer Therapy

  2007cites this paper
• UvA-DARE (Digital Academic Repository) In vitro studies on radiation effects and radiosensitization: HDR vs LDR and cytotoxic agents

  2007cites this paper
• Combined modality therapy of gemcitabine and irradiation on human glioma spheroids derived from cell lines and biopsy tissue.

  2006cites this paper
• Gemcitabine treatment of experimental C6 glioma: the effects on cell cycle and apoptotic rate.

  2006cites this paper
• Glucocorticoid use in prostate cancer and other solid tumours: implications for effectiveness of cytotoxic treatment and metastases.

  2006cites this paper
• In vitro genotoxic effects of the anticancer drug gemcitabine in human lymphocytes.

  2005cites this paper
• Activation of c‐Jun NH2‐terminal kinase is required for gemcitabine's cytotoxic effect in human lung cancer H1299 cells

  2005cites this paper
• Substrate cycles and drug resistance to 1-beta-D-arabinofuranosylcytosine (araC)

  2005cites this paper
• Use of cell therapy as a means of targeting chemotherapy to inoperable pancreatic cancer.

  2005cites this paper
• [Metabolism, mechanism of action and resistance to cytotoxic nucleoside analogues].

  2005cites this paper
• Interference of glucocorticoids with apoptosis signaling and host-tumor interactions

  2004cites this paper
• Promising combination therapies with gemcitabine.

  2004cites this paper
• Time-dependent Inhibition of Glioblastoma Cell Proliferation by Dexamethasone

  2004cites this paper
• Pyrimidine nucleoside analogs in cancer treatment

  2003cites this paper
• Enhancement of effects of irradiation by gemcitabine in a glioblastoma cell line and cell line spheroids

  2003cites this paper
• Increased sensitivity to gemcitabine of P-glycoprotein and multidrug resistance-associated protein-overexpressing human cancer cell lines

  2003cites this paper
• Identification of novel cellular targets in biliary tract cancers using global gene expression technology.

  2003cites this paper
• Preclinical development of biodegradable polymer foils for intracerebral delivery of cytotoxic nucleosides.

  2003cites this paper
• Drug resistance to cytotoxic nucleoside analogues.

  2003cites this paper
• Medical decompressive therapy for primary and metastatic intracranial tumours.

  2003cites this paper
• Safety and efficacy of convection-enhanced delivery of gemcitabine or carboplatin in a malignant glioma model in rats.

  2003cites this paper
• In vitro studies on the immunosuppressive effect of 2',2'-difluorodeoxycytidine (dFdC) and its metabolite 2',2'-difluorodeoxyuridine (dFdU).

  2003cites this paper
• Safety, feasibility and clinical benefit of localized chemotherapy using microencapsulated cells for inoperable pancreatic carcinoma in a phase I/II trial

  2003cites this paper
• Expression of a non‐functional p53 affects the sensitivity of cancer cells to gemcitabine

  2002cites this paper
• Nucleoside analogues and nucleobases in cancer treatment.

  2002cites this paper
• Treatment of inoperable pancreatic carcinoma using a cell-based local chemotherapy: results of a phase I/II clinical trial.

  2002cites this paper
• A Review of Recent Results Addressing the Potential Interactions of Antioxidants with Cancer Drug Therapy

  2001cites this paper
• The Molecular Genetics of Therapeutic Resistance in Malignant Astrocytomas

  2001cites this paper
• Steroids affect collateral sensitivity to gemcitabine of multidrug-resistant human lung cancer cells.

  2001cites this paper
• Enhancement of tumor radioresponse by combined chemotherapy in murine hepatocarcinoma 1

  2001cites this paper
• Radiosensitization by gemcitabine in p53 wild-type and mutant MCF-7 breast carcinoma cell lines.

  2001cites this paper
• Preirradiation gemcitabine chemotherapy for newly diagnosed glioblastoma

  2001cites this paper
• Antineoplastic activity of a novel multimeric gemcitabine-monophosphate prodrug against thyroid cancer cells in vitro.

  2000cites this paper
• NCIC-CTG phase II study of gemcitabine in patients with malignant glioma (IND.94).

  2000cites this paper
• Cytotoxic Activity of 2′,2′-Difluorodeoxycytidine (Gemcitabine) in Poorly Differentiated Thyroid Carcinoma Cells

  2000cites this paper
• The role of cell cycle progression in radiosensitization by 2',2'-difluoro-2'-deoxycytidine.

  2000cites this paper
• Chemotherapy and immunotherapy of malignant glioma: molecular mechanisms and clinical perspectives

  1999cites this paper